Growth hormone as concomitant treatment in severe fibromyalgia associated with low IGF-1 serum levels. A pilot study
2007

Growth Hormone Treatment for Severe Fibromyalgia

Sample size: 24 publication Evidence: moderate

Author Information

Author(s): Cuatrecasas Guillem, Riudavets Cristina, Güell Maria Antònia, Nadal Albert

Primary Institution: Centro Médico Teknon, Barcelona, Spain

Hypothesis

Does adding low dose growth hormone to standard therapy improve outcomes in fibromyalgia patients with low IGF-1 levels?

Conclusion

Adding a daily dose of growth hormone to standard therapy significantly reduces tender points and improves quality of life in severe fibromyalgia patients with low IGF-1 levels.

Supporting Evidence

  • The GH group showed a 60% reduction in tender points compared to the control group.
  • Significant improvements were observed in the Fibromyalgia Impact Questionnaire and EQ-VAS scores.
  • Most patients in the GH group experienced improvement within the first months.

Takeaway

This study found that giving growth hormone to people with severe fibromyalgia and low IGF-1 levels helped reduce their pain and improve their quality of life.

Methodology

A randomized, open-label, controlled trial with 24 patients receiving either growth hormone or standard therapy for one year.

Potential Biases

Potential bias due to the open-label design.

Limitations

The study lacked a placebo group and had a small sample size.

Participant Demographics

All participants were women with a mean age of 48.5 years.

Statistical Information

P-Value

p < 0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1471-2474-8-119

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication